| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/13543784.2011.613822 |
| P698 | PubMed publication ID | 21888556 |
| P2093 | author name string | Lia Gore | |
| Jeffrey Knipstein | |||
| P2860 | cites work | Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents | Q21198868 |
| Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) | Q24681480 | ||
| Histone deacetylases and cancer | Q28240447 | ||
| Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions | Q30873726 | ||
| FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma | Q33377159 | ||
| Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma | Q33386623 | ||
| A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas | Q33619776 | ||
| Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors | Q33697130 | ||
| Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells | Q33778532 | ||
| Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation | Q33863049 | ||
| DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. | Q34111103 | ||
| The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. | Q34334999 | ||
| Deacetylation of the DNA-binding domain regulates p53-mediated apoptosis | Q34575823 | ||
| Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole | Q34789970 | ||
| A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors | Q35134137 | ||
| NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells | Q35850681 | ||
| MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. | Q36608545 | ||
| Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts | Q36642487 | ||
| Histone deacetylase inhibitors: molecular mechanisms of action | Q36908440 | ||
| Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. | Q36937117 | ||
| Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. | Q37287542 | ||
| ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). | Q37293403 | ||
| Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. | Q37372837 | ||
| Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition | Q37486272 | ||
| Clinical studies of histone deacetylase inhibitors. | Q37512917 | ||
| Romidepsin for the treatment of cutaneous T-cell lymphoma | Q37686109 | ||
| Histone deacetylase inhibitors in lymphoma | Q37777594 | ||
| Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model | Q39609163 | ||
| MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo | Q39637308 | ||
| Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275 | Q39672429 | ||
| HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells | Q39706886 | ||
| MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells | Q39784007 | ||
| Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. | Q39825708 | ||
| HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines | Q39825954 | ||
| Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor | Q39878333 | ||
| Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells | Q39889318 | ||
| Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells | Q39915669 | ||
| Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer | Q39938863 | ||
| Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics | Q39946149 | ||
| Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells | Q39948537 | ||
| Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models | Q39970361 | ||
| Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells | Q40088575 | ||
| Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models | Q40129051 | ||
| Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells | Q40135808 | ||
| Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood | Q40182103 | ||
| Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells | Q40198503 | ||
| Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases | Q40268068 | ||
| Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. | Q40327522 | ||
| Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma | Q40427871 | ||
| Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation | Q40511181 | ||
| Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells | Q40569136 | ||
| Identification of novel isoform-selective inhibitors within class I histone deacetylases | Q40634385 | ||
| Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells | Q41807496 | ||
| HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression | Q42461306 | ||
| Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells | Q43066875 | ||
| Sp1-mediated TRAIL induction in chemosensitization | Q43193517 | ||
| Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. | Q44732875 | ||
| The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. | Q44826959 | ||
| The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells | Q44872972 | ||
| Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma | Q46167944 | ||
| Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives | Q46235693 | ||
| Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells | Q46375225 | ||
| Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma | Q46455509 | ||
| Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma | Q46484454 | ||
| HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma | Q46494095 | ||
| Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor | Q46607495 | ||
| MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells | Q46659826 | ||
| Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell | Q46815322 | ||
| Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. | Q48519096 | ||
| Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. | Q50650942 | ||
| Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. | Q52579549 | ||
| Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. | Q53536794 | ||
| Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis | Q57374741 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | entinostat | Q1281020 |
| P304 | page(s) | 1455-1467 | |
| P577 | publication date | 2011-09-02 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Entinostat for treatment of solid tumors and hematologic malignancies | |
| P478 | volume | 20 |
| Q34559028 | Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling |
| Q91785090 | Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells |
| Q39185574 | Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response |
| Q30886620 | Comparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families. |
| Q48200103 | E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. |
| Q33432027 | ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma |
| Q38534163 | Entinostat (SNDX-275) for the treatment of non-small cell lung cancer |
| Q37260765 | Entinostat up-regulates the CAMP gene encoding LL-37 via activation of STAT3 and HIF-1α transcription factors |
| Q38741783 | Entinostat: a promising treatment option for patients with advanced breast cancer |
| Q58130496 | Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types |
| Q92104678 | Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models |
| Q39177415 | Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells |
| Q37962333 | HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications |
| Q38947405 | HDACs and HDAC Inhibitors in Cancer Development and Therapy |
| Q34496371 | Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells |
| Q37437269 | MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer |
| Q64062988 | Novel aroylated phenylenediamine compounds enhance antimicrobial defense and maintain airway epithelial barrier integrity |
| Q50023818 | Novel therapeutics in glaucoma management |
| Q39047967 | Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer. |
| Q36938662 | Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a |
| Q37298877 | Rapid screening of novel agents for combination therapy in sarcomas |
| Q39062353 | Selective histone deacetylase small molecule inhibitors: recent progress and perspectives |
| Q89169966 | Targeting Epigenetics in Cancer |
| Q38051736 | Targeting class I histone deacetylases in cancer therapy |
| Q92179985 | Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer |
| Q34956310 | The class I histone deacetylase inhibitor MS-275 prevents pancreatic beta cell death induced by palmitate. |
| Q41883101 | The effect of MS-275 on CYP450 isoforms activity in rats by cocktail method |
| Q27000542 | Trials with 'epigenetic' drugs: an update |
Search more.